Research Analysts Set Expectations for RDY Q2 Earnings

Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Stock analysts at Zacks Research upped their Q2 2027 EPS estimates for Dr. Reddy's Laboratories in a research note issued on Wednesday, October 16th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.78 per share for the quarter, up from their prior estimate of $0.77. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $4.11 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' FY2027 earnings at $3.13 EPS.

Get RDY alerts:

Separately, Barclays raised their price objective on shares of Dr. Reddy's Laboratories from $81.00 to $87.00 and gave the company an "overweight" rating in a report on Tuesday, July 30th.

Read Our Latest Stock Report on RDY

Dr. Reddy's Laboratories Trading Down 0.2 %

Shares of RDY stock traded down $0.15 during mid-day trading on Friday, reaching $79.65. 145,370 shares of the stock traded hands, compared to its average volume of 212,901. The company has a market cap of $13.29 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 1.73 and a beta of 0.55. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The stock's fifty day simple moving average is $80.46 and its two-hundred day simple moving average is $76.31. Dr. Reddy's Laboratories has a 1-year low of $63.72 and a 1-year high of $84.46.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings data on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.10 by ($0.10). Dr. Reddy's Laboratories had a return on equity of 20.32% and a net margin of 19.28%. The firm had revenue of $919.80 million for the quarter, compared to the consensus estimate of $861.68 million.

Ad Behind the Markets

Unveiled: NVIDIA’s "Secret Royalty" Program

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

Institutional Trading of Dr. Reddy's Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of RDY. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Dr. Reddy's Laboratories by 318.0% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company's stock valued at $28,411,000 after acquiring an additional 283,700 shares during the last quarter. Millennium Management LLC increased its position in shares of Dr. Reddy's Laboratories by 61.4% during the second quarter. Millennium Management LLC now owns 332,502 shares of the company's stock worth $25,333,000 after buying an additional 126,472 shares during the period. Dimensional Fund Advisors LP raised its stake in Dr. Reddy's Laboratories by 12.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock worth $76,455,000 after buying an additional 114,294 shares during the last quarter. Jane Street Group LLC lifted its holdings in Dr. Reddy's Laboratories by 2,197.8% in the first quarter. Jane Street Group LLC now owns 113,168 shares of the company's stock valued at $8,301,000 after buying an additional 108,243 shares during the period. Finally, National Bank of Canada FI boosted its position in Dr. Reddy's Laboratories by 81.6% during the second quarter. National Bank of Canada FI now owns 184,120 shares of the company's stock valued at $13,884,000 after acquiring an additional 82,724 shares during the last quarter. 14.02% of the stock is currently owned by institutional investors and hedge funds.

About Dr. Reddy's Laboratories

(Get Free Report)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Should you invest $1,000 in Dr. Reddy's Laboratories right now?

Before you consider Dr. Reddy's Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.

While Dr. Reddy's Laboratories currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report